Skip to main content
SpringerLink
Log in

Was wirkt und was nicht?

  • Chapter
  • First Online:
Hirndoping & Co.

  • 2245 Accesses

Zusammenfassung

OTC-Drugs (zum Beispiel Koffein, Ginkgo biloba), verschreibungspflichtige Medikamente (zum Beispiel Ritalin®, Attentin®, Adderall®) und illegale Drogen (zum Beispiel Speed, Crystal Meth) haben sehr unterschiedliche Einflüsse auf die geistige Leistungsfähigkeit. Tendenziell sind die Wirkungen von koffeinhaltigen Mitteln, Amphetaminen und Modafinil am ausgeprägtesten auf kognitive Domänen wie Vigilanz, Aufmerksamkeit, Konzentration und Gedächtnisleistungen. Dabei ist die Wirkung von Koffein geringer als die von Modafinil; Amphetamine sind am wirkungsvollsten. Die Wirkung der Neuroenhancer ist umso ausgeprägter, je beeinträchtigter – im Sinne von müde – die Einnehmenden im Vorfeld sind.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 9.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Referenzen und Literatur zum Weiterlesen

Allgemein

  1. Benkert O & Hippius H (2019) Kompendium der Psychiatrischen Pharmakotherapie. (12. Aufl.) Springer-Verlag

    Google Scholar 

  2. de Jongh R et al (2008) Botox for the brain: enhancement of cognition, mood and pro-social behavior and blunting of unwanted memories. Neurosci Biobehav Rev 32:760–776

    Article  Google Scholar 

  3. Franke AG et al (2014) Substances used and prevalence rates of pharmacological cognitive enhancement among healthy subjects. Eur Arch of Psychiatry Clin Neurosci 264(Suppl 1):83–90

    Article  Google Scholar 

  4. Franke AG, Lieb K (2009) Missbrauch von Psychopharmaka zum „Cognitive Enhancement“. Mit Hirndoping zu intellektuellen Spitzenleistungen? InFo Neurologie Psychiatrie 11(7–8):42–51

    Google Scholar 

  5. Mehlman MJ (2004) Cognition-enhancing drugs. The Milbank Q 82(3):483–506

    Article  Google Scholar 

Koffein

  1. Aggarwal R et al (2011) Effect of caffeine and taurine on simulated laparoscopy performed following sleep deprivation. Br J Surg 98(11):1666–1672

    Article  Google Scholar 

  2. Alford C et al (2001) The effects of red bull energy drink on human performance and mood. Amino Acids 21:139–150

    Article  Google Scholar 

  3. Fisone G et al (2004) Caffeine as a psychomotor stimulant: mechanism of action. Cell Mol Life Sci 61:857–872

    Article  Google Scholar 

  4. Franke AG et al (2017) Methylphenidate, modafinil, and caffeine for cognitive enhancement in chess: a double-blind, randomised controlled trial. Eur Neuropsychopharmacol 27(3):248–260

    Article  Google Scholar 

  5. Ishak WW et al (2012) Energy drinks: psychological effects and impact onwell-being and quality of life – a literature review. Innovations in Clin Neurosci 9:25–34

    Google Scholar 

  6. Ker K et al (2010) Caffeine for the prevention of injuries and errors in shift workers. Cochrane Database Syst Rev 5:CD008508

    Google Scholar 

  7. Killgore WD et al (2008) Effects of dextroamphetamine, caffeine and modafinil on psychomotor vigilance test performance after 44 h of continuous wakefulness. J Sleep Res 17:309–321

    Article  Google Scholar 

  8. Killgore WD et al (2009) Sustaining executive functions during sleep deprivation: A comparison of caffeine, dextroamphetamine, and modafinil. Sleep 32:205–216

    Article  Google Scholar 

  9. Lin FJ et al (2010) Effect of taurine and caffeine on sleepwake activity in Drosophila melanogaster. Nat and Sci of Sleep 2:221–231

    Article  Google Scholar 

  10. Miller KE (2008) Wired: energy drinks, jock identity, masculine norms, and risk taking. J Am Coll Health 56:481–489

    Article  Google Scholar 

  11. Nehlig A et al (1992) Caffeine and the central nervous system: mechanisms of action, biochemical, metabolic and psychostimulant effects. Brain Res Rev 17:139–170

    Article  Google Scholar 

  12. Nestle M (2000) Soft drink „Pouring Rights“: marketing empty calories to children. Pub Health Rep 115(4):308–319

    Article  Google Scholar 

  13. Preedy V (2015) Coffee in health and disease prevention, 1. Aufl. Elsevier, Amsterdam

    Google Scholar 

  14. Wesensten NJ (2014) Legitimacy of concerns about caffeine and energy drink consumption. Nutr Rev 72(Suppl. 1):78–86

    Article  Google Scholar 

Ginkgo biloba

  1. Birks J, Grimley Evans J (2009) Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Systematic Reviews (1):CD003120

    Google Scholar 

  2. Burns NR et al (2006) Ginkgo biloba: no robust effect on cognitive abilities or mood in healthy young or older adults. Hum Psychopharmacol 21:27–37

    Article  Google Scholar 

  3. Franke AG et al (2014) Substances used and prevalence rates of pharmacological cognitive enhancement among healthy subjects. Eur Arch Psychiatry Clin Neurosci 264(Suppl 1):83–90

    Article  Google Scholar 

  4. Franke AG, Lieb K (2009) Missbrauch von Psychopharmaka zum „Cognitive Enhancement“. Mit Hirndoping zu intellektuellen Spitzenleistungen? InFo Neurol Psychiatr 11(7–8):42–51

    Google Scholar 

  5. Kennedy DO et al (2002) Modulation of cognition and mood following administration of single doses of Ginkgo biloba, ginseng, and a ginkgo/ginseng combination to healthy young adults. Physiol Behav 75:739–751

    Article  Google Scholar 

  6. Scholey AB (2002) Acute, dose-dependent cognitive effects of Ginkgo biloba, Panax ginseng and their combination in healthy young volunteers: differential interactions with cognitive demand. Hum Psychopharmacol 17:35–44

    Article  Google Scholar 

  7. Solomon PR et al (2002) Ginkgo for memory enhancement: a randomized controlled trial. J Am Med Assoc 288:835–840

    Article  Google Scholar 

  8. Zhang HF et al (2016) An Overview of Systematic Reviews of Ginkgo biloba Extracts for Mild Cognitive Impairment and Dementia. Frontiers in Aging Neuroscience 8:276. https://doi.org/10.3389/fnagi.2016.00276 eCollection 2016

    Article  Google Scholar 

Antidementiva

  1. de Jongh R et al. (2008) Botox for the brain: enhancement of cognition, mood and pro-social behavior and blunting of unwanted memories. Neuroscience & Biobehavioral Reviews 32:760–776

    Google Scholar 

  2. Franke AG, Lieb K (2009) Missbrauch von Psychopharmaka zum „Cognitive Enhancement“. Mit Hirndoping zu intellektuellen Spitzenleistungen? InFo Neurologie Psychiatrie 11(7–8):42–51

    Google Scholar 

  3. Franke AG et al. (2014) Substances used and prevalence rates of pharmacological Cognitive Enhancement among healthy subjects. European Archives of Psychiatry and Clinical Neurosciences 264 Suppl 1:83–90

    Google Scholar 

  4. Rammsayer TH (2001) Effects of pharmacologically induced changes in NMDA-receptor activity on long-term memory in humans. Learn & Mem 8:20–25

    Article  Google Scholar 

  5. Rammsayer TH (2001) Effects of pharmacologically induced changes in NMDA receptor activity on human timing and sensorimotor performance. Brain Res 1073–1074:407–416

    Google Scholar 

Modafinil

  1. Bagot KS, Kaminer Y (2014) Efficacy of stimulants for cognitive enhancement in non-attention deficit hyperactivity disorder youth: a systematic review. Addiction 109:547–557

    Article  Google Scholar 

  2. Blaeser-Kiel G (2006) Schichtarbeiter-Syndrom: Es rächt sich, die innere Uhr zu ignorieren. Deutsches Ärzteblatt 103(7):A-424

    Google Scholar 

  3. Franke AG et al. (2017) Methylphenidate, modafinil, and caffeine for Cognitive Enhancement in chess: A double-blind, randomised controlled trial. European Neuropsychopharmacology 27(3):248–260

    Google Scholar 

  4. Jongh R de et al. (2008) Botox for the brain: enhancement of cognition, mood and pro-social behavior and blunting of unwanted memories. Neuroscience & Biobehavioral Reviews 32:760–776

    Google Scholar 

  5. Killgore WD (2008) Effects of dextroamphetamine, caffeine and modafinil on psychomotor vigilance test performance after 44 h of continuous wakefulness. Journal of Sleep Research 17:309–321

    Google Scholar 

  6. Killgore WD (2009) Sustaining executive functions during sleep deprivation: A comparison of caffeine, dextroamphetamine, and modafinil. Sleep 32:205–216

    Google Scholar 

  7. Minzenberg MJ, Carter CS (2008) Modafinil: a review of neurochemical actions and effects on cognition. Neuropsychopharmacol 33:1477–1502

    Article  Google Scholar 

  8. Sugden C et al (2012) Effect of pharmacological enhancement on the cognitive and clinical psychomotor performance of sleep-deprived doctors: a randomized controlled trial. Ann Surg 255(2):222–227

    Article  Google Scholar 

Amphetamine

  1. Bagot KS, Kaminer Y (2014) Efficacy of stimulants for Cognitive Enhancement in non-attention deficit hyperactivity disorder youth: a systematic review. Addiction 109:547–557

    Google Scholar 

  2. Baumgärtner M et al (2015) Crystal Meth: Produzenten, Dealer, Ermittler. Ch. Links Verlag GmbH, Berlin

    Google Scholar 

  3. Daumann J, Gouzoulis-Mayfrank E (2015) Amphetamine, Ecstasy und Designerdrogen. Kohlhammer, Stuttgart

    Google Scholar 

  4. de Jongh R et al. (2008) Botox for the brain: enhancement of cognition, mood and pro-social behavior and blunting of unwanted memories. Neuroscience & Biobehavioral Reviews 32:760–776

    Google Scholar 

  5. Franke AG et al. (2017) Methylphenidate, modafinil, and caffeine for Cognitive Enhancement in chess: A double-blind, randomised controlled trial. European Neuropsychopharmacology 27(3):248–260

    Google Scholar 

  6. Iversen L (2009) Speed, Ecstasy, Ritalin: Amphetamine-Theorie und Praxis. Huber, Bern

    Google Scholar 

  7. Killgore WD (2008) Effects of dextroamphetamine, caffeine and modafinil on psychomotor vigilance test performance after 44 h of continuous wakefulness. Journal of Sleep Research 17:309–321

    Google Scholar 

  8. Killgore WD (2009) Sustaining executive functions during sleep deprivation: A comparison of caffeine, dextroamphetamine, and modafinil. Sleep 32:205–216

    Google Scholar 

  9. Neumann S et al (2016) Methamphetaminabhängigkeit in Deutschland. Eine selektive Übersicht über Epidemiologie, Phänomenologie und Therapie. Nervenheilkunde 35(11):742–747

    Article  Google Scholar 

  10. Rasmussen N (2011) Medical science and the military: the Allies’ use of amphetamine during World War II. J Interdiscip Hist 42(2):205–233

    Article  Google Scholar 

  11. Spencer RC et al (2012) Psychostimulants act within the prefrontal cortex to improve cognitive function. Biol Psychiatry 72:221–227

    Article  Google Scholar 

  12. Wesensten NJ et al (2005) Performance and alertness effects of caffeine, dextroamphetamine, and modafinil during sleep deprivation. J Sleep Res 14(3):255–266

    Article  Google Scholar 

Antidepressiva

  1. Elliott C (2003) Better than well: American medicine meets the American dream. WW Norton, New York

    Google Scholar 

  2. Hall W (2004) Feeling „better than well“. EMBO Rep 5(12):1105–1109

    Article  Google Scholar 

  3. Harmer CJ et al (2003) Acute SSRI administration affects the processing of social cues in healthy volunteers. Neuropsychopharmacol 28:148–152

    Article  Google Scholar 

  4. Harmer CJ et al (2004) Increased positive versus negative affective perception and memory in healthy volunteers following selective serotonin and norepinephrine reuptake inhibition. Am J Psychiatry 161:1256–1263

    Article  Google Scholar 

  5. Knutson B et al (1998) Selective alteration of personality and social behavior by serotonergic intervention. Am J Psychiatry 155:333–339

    Article  Google Scholar 

  6. Kramer P (1993) Listening to prozac. Penguin, New York

    Google Scholar 

  7. Tse W, Bond A (2002) Serotonergic intervention affects both social dominance and affiliative behavior. Psychopharmacolo 161:373–379

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hochschule der Bundesagentur für Arbeit, Mannheim, Deutschland

    Andreas G. Franke

Authors
  1. Andreas G. Franke
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andreas G. Franke .

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Franke, A. (2019). Was wirkt und was nicht?. In: Hirndoping & Co.. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-58853-6_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-58853-6_8

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-58852-9

  • Online ISBN: 978-3-662-58853-6

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation